CONTEXT: The ability of a transplant recipient to accept a graft depends on the ability of immunosuppressive drugs to regulate the immune system.
Such treatments have been associated with tumor promotion and progression.
EVIDENCE ACQUISITION: A systematic literature review was carried out. Electronic searches were performed in PubMed database. The searching criterion was «urological tumors in kidney transplant recipients». The most important issues regarding incidence, urological tumor-specific features, and relevant ones about the treatment are summarized.
SYNTHESIS OF EVIDENCE: In renal transplant, 15%of alltumors are urological neoplasias; furthermore, they are the leading neoplastic cause of death. In transplant population the incidence rate of renal cell carcinoma (RCC), transitional cellbladder carcinoma (TCBC), testicular carcinoma (TC) and prostate cancer are increased 15, 3, 3 and 2 times respectively. Treatments used in transplant patients are similar to those employed in the general population:radical nephrectomy for the native kidney and conservative surgery for the graft are indicated for RCC. Radical prostatectomy is technically feasible for localized PC. Regarding to transitional cell carcinoma BCG or MMC is not contraindicated.
CONCLUSIONS: The incidence rate of cancer has increased among transplant population. These tumors can be managed following the same criteria than in general population. Because in this population the prognosis is worse for the immunosuppression, closer monitoring is required.
Written by:
Rodríguez Faba O, Breda A, Gausa L, Palou J, Villavicencio H. Are you the author?
Unidad de Trasplante Renal, Servicio de Urología, Fundació Puigvert, Barcelona, España; Unidad de Urología Oncológica, Servicio de Urología, Fundació Puigvert, Barcelona, España.
Reference: Actas Urol Esp. 2014 Jul 1. pii: S0210-4806(14)00168-5.
doi: 10.1016/j.acuro.2014.05.002
PubMed Abstract
PMID: 24996779
Article in English, Spanish.
UroToday.com Renal & Vascular Diseases Section
